N. Anthony Coles net worth and biography

N. Coles Biography and Net Worth

Dr. Coles is the Executive Chairman and Chief Executive Officer of Cerevel Therapeutics, a Bain-portfolio biotechnology company specializing in the development of new therapies for diseases of the central nervous system. Previously, Dr. Coles served as co-founder and Chief Executive Officer of Yumanity Therapeutics, LLC, from October 2014 until September 2019, and he continues to serve as the Executive Chair of the Board. Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biopharmaceutical company. Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company, and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Dr. Coles has been a director of McKesson Corporation since April 2014 and serves on the Compensation Committee and the Finance Committee of its board of directors.

What is N. Anthony Coles' net worth?: The estimated net worth of N. Anthony Coles is at least $14.13 million as of March 4th, 2024. Dr. Coles owns 15,638 shares of Regeneron Pharmaceuticals stock worth more than $14,128,620 as of May 1st. This net worth evaluation does not reflect any other assets that Dr. Coles may own. Learn More about N. Anthony Coles' net worth.
How do I contact N. Anthony Coles?: The corporate mailing address for Dr. Coles and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on N. Anthony Coles' contact information.
Has N. Anthony Coles been buying or selling shares of Regeneron Pharmaceuticals?: N. Anthony Coles has not been actively trading shares of Regeneron Pharmaceuticals during the past quarter. Most recently, N Anthony Coles sold 5,758 shares of the business's stock in a transaction on Wednesday, December 28th. The shares were sold at an average price of $714.11, for a transaction totalling $4,111,845.38. Following the completion of the sale, the director now directly owns 1,093 shares of the company's stock, valued at $780,522.23. Learn More on N. Anthony Coles' trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 30 times. They sold a total of 72,863 shares worth more than $63,789,579.06. The most recent insider tranaction occured on March, 14th when EVP Andrew J Murphy sold 5,783 shares worth more than $5,531,266.01. Insiders at Regeneron Pharmaceuticals own 8.8% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 3/14/2024.

N. Anthony Coles Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/28/2022	Sell	5,758	$714.11	$4,111,845.38	1,093
9/15/2021	Sell	11,948	$658.98	$7,873,493.04	7,811

N. Anthony Coles Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $903.48

$888.52

$913.21

50 Day Range

MA: $945.77

$883.20

$993.35

2 Week Range

Now: $903.48

$684.80

$998.33

Volume

586,202 shs

Average Volume

492,499 shs

Market Capitalization

$99.17 billion

P/E Ratio

26.00

Dividend Yield

N/A

Beta

0.11

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report